Statute Details
- Title: Medicines (Labelling) Regulations
- Act Code: MA1975-RG5
- Legislative Type: Subsidiary legislation (sl)
- Authorising Act: Medicines Act (Chapter 176), Section 44
- Current status (as provided): Current version as at 27 Mar 2026
- Key provisions (from extract):
- Regulation 3: Definitions
- Regulation 3A: Scope of Regulations / exclusions
- Regulation 4: Particulars to be shown on label (dispensed medicinal products)
- Regulation 6: Certain substances to be labelled (First Schedule)
- Regulation 7: Products to carry date stamp (Second Schedule)
- Regulation 8: Exceptions to date-stamp requirement
- Regulation 9: Label format: dimensions, position, legibility
- Schedules: First Schedule (certain substances); Second Schedule (substances triggering “Use by”/expiry labelling)
- Notable amendments (from legislative history):
- S 545/2016 (effective 01/11/2016) — includes deletion of Regulations 2 and 5 in the extract and adds Regulation 3A scope exclusions
- Revisions/updates: 2000 RevEd; earlier amendments in 1997–1999
- Commencement date: Not shown in the provided extract
What Is This Legislation About?
The Medicines (Labelling) Regulations impose detailed requirements on how medicinal products must be labelled in Singapore. In practical terms, the Regulations are designed to ensure that consumers, patients, and healthcare professionals can identify what a medicine is, who it is for (in the case of dispensed medicines), how it should be used, and—where relevant—whether it contains certain substances or has an expiry (“Use by”) date.
The Regulations operate as a compliance framework under the Medicines Act. They do not attempt to regulate clinical efficacy or prescribing decisions. Instead, they focus on information disclosure at the point of sale, supply, and dispensing. This is particularly important in a retail environment where medicines may be purchased by the public, and where incorrect or missing labelling can create safety risks (for example, use of expired products, or failure to disclose the presence of specified substances).
The Regulations also draw a careful distinction between “dispensed medicinal products” and other medicinal products sold or supplied in circumstances corresponding to retail sale, as well as products dealt with by wholesale. That distinction drives which labelling particulars are mandatory and which additional requirements (such as “Use by” dates or substance declarations) apply.
What Are the Key Provisions?
1. Definitions and interpretive anchors (Regulation 3)
The Regulations define key terms that determine the scope and content of labelling. For example, “appropriate non-proprietary name” is defined by reference to recognised compendia (European Pharmacopoeia, British Pharmacopoeia, US Pharmacopoeia National Formulary, Pharmaceutical Codex (British), and British National Formulary) or, where applicable, an international non-proprietary name selected by the World Health Organisation. This matters because labelling must use the correct naming convention for the medicine and, in certain circumstances, for active ingredients.
Similarly, “appropriate quantitative particulars” is defined to require the quantity of each active ingredient in terms of weight, volume, capacity, units of activity, or percentage by weight/volume. This is relevant where the Regulations require quantitative disclosure on labels (notably for dispensed medicinal products when the appropriate non-proprietary name is used).
2. Scope exclusions (Regulation 3A)
Regulation 3A provides that the Regulations do not apply to: (a) “Chinese proprietary medicines”; and (b) any medicinal product (other than a Chinese proprietary medicine) that is “clinical research material” as defined in the Medicines (Medicinal Products as Clinical Research Materials) Regulations 2016. This is a significant compliance point: manufacturers and distributors dealing with Chinese proprietary medicines or clinical research materials should not assume that the labelling requirements in these Regulations apply.
3. Dispensed medicinal products: mandatory label particulars (Regulation 4)
Regulation 4 is the core rule for dispensed medicines. Where a medicinal product is a “dispensed medicinal product,” the container must be labelled with specific particulars. These include: (a) the name of the person to whom the medicine is to be administered; (b) the name and address of the medical or dental practice, registered pharmacy, hospital, or other institution where it is supplied or dispensed, together with any identification number or mark; (c) the date on which it was dispensed; (d) directions for use; (e) the name of the medicinal product, either the appropriate non-proprietary name or the proprietary designation; and (f) where the appropriate non-proprietary name is labelled, the appropriate quantitative particulars of the active ingredients.
For practitioners advising pharmacies, hospitals, and dispensing doctors, Regulation 4 is a checklist provision. It is also a reminder that “directions for use” and patient identification are not optional. In enforcement terms, missing particulars can be treated as non-compliance even if the medicine itself is otherwise lawful.
4. Certain substances: substance declaration labelling (Regulation 6 and First Schedule)
Regulation 6 applies when a medicinal product for human consumption or use contains any substance specified in the First Schedule, is not a dispensed medicinal product, and is sold by retail (or supplied in circumstances corresponding to retail sale) or is possessed for such sale/supply. The rule requires that every container—and where immediately enclosed, the package—be labelled in English with a statement declaring the presence of that substance.
The statement may describe the substance using a corresponding term specified in the First Schedule or any other equivalent term. This flexibility can be important for brand owners and importers, but it also creates a compliance risk: “equivalent term” must be sufficiently accurate to avoid misleading labelling.
5. Expiry labelling: “Use by” requirement (Regulation 7, Second Schedule)
Regulation 7 requires date stamping for medicinal products containing substances specified in the Second Schedule (again, where the product is not a dispensed medicinal product). The trigger is broader than retail sale: it covers wholesale dealing, retail sale, and possession for such sale/supply. Every container and, where immediately enclosed, every package must be labelled with the words “Use by” (or similar words) followed by the expiry date.
6. Exceptions to “Use by” labelling (Regulation 8)
Regulation 8 carves out specific exceptions to the date-stamp requirement. The extract shows two key exceptions:
- Ascorbic acid (Vitamin C) confectionery: Regulation 7 does not apply to products containing ascorbic acid (Vitamin C) or its salts sold as confectionery, provided the product is not (and is not to be sold with) particulars in writing specifying curative or remedial functions, or use for curative/remedial purposes in relation to a disease specified on the container other than coughs, colds, or nasal congestion.
- Wholesale ingredient-only products: Regulation 7 does not apply to products comprising wholly of substances specified in the Second Schedule that are sold or supplied by way of wholesale dealing for use mainly as an ingredient in preparing another substance or article to be administered for medicinal purposes.
These exceptions are highly fact-sensitive. For example, the Vitamin C exception depends on how the product is marketed and whether disease-related claims are made. The wholesale ingredient exception depends on the intended use (“mainly as an ingredient”) and the downstream medicinal purpose.
7. Label format: size, legibility, and placement (Regulation 9)
Regulation 9 sets minimum standards for how label information must appear. It requires that all particulars required by the Regulations be printed in letters not less than 1.5 millimetres in height, clearly legible, and conspicuously in a prominent position on the label so they are easily read by an intending purchaser or user under normal conditions of purchase or use.
There is a practical accommodation: where the container or package is so small that the required size wording cannot be used, the statement may be printed in reduced size, provided it remains clearly legible. The Regulation also addresses blister or sealed unit packaging in continuous series (sheets or strips), deeming compliance where required particulars are displayed at frequent intervals on the sheet/strip. This is particularly relevant for unit-dose packaging and pharmaceutical blister packs.
Note: The extract truncates the remainder of Regulation 9 (for example, it begins “Every package immediately …” and cuts off). Practitioners should consult the full current version to ensure there are no additional formatting rules beyond what is shown in the extract.
How Is This Legislation Structured?
The Regulations are structured as a set of numbered regulations supported by two schedules. The early regulations provide definitions and scope. The substantive requirements then move from (i) dispensed medicinal products (Regulation 4), to (ii) non-dispensed products containing specified substances (Regulation 6), to (iii) expiry labelling for products containing specified substances (Regulation 7), and then to (iv) exceptions (Regulation 8). Finally, Regulation 9 provides general rules on label presentation—font size, legibility, conspicuousness, and how to comply when packaging is small or arranged in blister/continuous series formats.
The schedules function as “trigger lists.” The First Schedule identifies substances that require a presence declaration on labels. The Second Schedule identifies substances that require “Use by”/expiry labelling. This design means that the labelling obligations can change over time if the schedules are amended, even if the core regulations remain the same.
Who Does This Legislation Apply To?
In general, the Regulations apply to medicinal products for human consumption or use that are sold or supplied in Singapore, or are possessed for such sale/supply, subject to the exclusions in Regulation 3A. The obligations differ depending on whether the product is a “dispensed medicinal product” (Regulation 4) or a product sold/supplied in retail-like circumstances or by wholesale dealing (Regulations 6 and 7).
Practically, the Regulations affect a wide range of stakeholders: dispensing doctors and dentists; registered pharmacies; hospitals and other institutions that supply medicines; wholesalers and distributors; and manufacturers/importers responsible for packaging and label content. However, Chinese proprietary medicines and clinical research materials (as defined in the 2016 clinical research materials regulations) are excluded from the Regulations’ application.
Why Is This Legislation Important?
Labelling is a frontline safety mechanism. These Regulations reduce the risk of patient harm by ensuring that dispensed medicines are correctly identified for the intended patient, include dispensing dates and directions for use, and—where relevant—include expiry information and substance declarations. For practitioners, this is not merely a technical compliance issue; it is a patient safety and consumer protection measure.
From an enforcement and litigation perspective, the Regulations create clear, objective obligations. Many requirements are checklist-based (for example, the particulars in Regulation 4). That clarity can be decisive in regulatory investigations and in disputes about whether a supplier met statutory duties.
For commercial actors, the Regulations also have operational implications. Packaging and label design must accommodate minimum font size and conspicuous placement. Where blister packs or small containers are used, the packaging format must still allow required particulars to be displayed at frequent intervals or in reduced but legible size. Compliance therefore requires coordination between regulatory counsel, quality assurance teams, and packaging vendors.
Related Legislation
- Medicines Act (Chapter 176), Section 44 (authorising provision for these Regulations)
- Medicines (Medicinal Products as Clinical Research Materials) Regulations 2016 (definition cross-reference for clinical research material in Regulation 3A)
- Medicines (Traditional Medicines, Homoeopathic Medicines and other Substances) (Exemption) Order (definition cross-reference for “Chinese proprietary medicines” in Regulation 3)
Source Documents
This article provides an overview of the Medicines (Labelling) Regulations for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.